- Home
- TVRD vs SSSS Comparison
TVRD vs SSSS Comparison
Compare TVRD & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- SSSS
- Stock Information
- Founded
- TVRD 2017
- SSSS 2010
- Country
- TVRD United States
- SSSS United States
- Employees
- TVRD N/A
- SSSS N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- TVRD Health Care
- SSSS Finance
- Exchange
- TVRD Nasdaq
- SSSS Nasdaq
- Market Cap
- TVRD 246.5M
- SSSS 220.7M
- IPO Year
- TVRD N/A
- SSSS N/A
- Fundamental
- Price
- TVRD $6.73
- SSSS $9.14
- Analyst Decision
- TVRD Buy
- SSSS Strong Buy
- Analyst Count
- TVRD 7
- SSSS 4
- Target Price
- TVRD $51.67
- SSSS $9.75
- AVG Volume (30 Days)
- TVRD 467.6K
- SSSS 213.0K
- Earning Date
- TVRD 11-21-2025
- SSSS 11-06-2025
- Dividend Yield
- TVRD N/A
- SSSS 10.78%
- EPS Growth
- TVRD N/A
- SSSS N/A
- EPS
- TVRD N/A
- SSSS 2.22
- Revenue
- TVRD N/A
- SSSS $2,784,381.00
- Revenue This Year
- TVRD N/A
- SSSS $7,183.09
- Revenue Next Year
- TVRD N/A
- SSSS N/A
- P/E Ratio
- TVRD N/A
- SSSS $4.18
- Revenue Growth
- TVRD N/A
- SSSS N/A
- 52 Week Low
- TVRD $5.65
- SSSS $4.21
- 52 Week High
- TVRD $43.65
- SSSS $10.05
- Technical
- Relative Strength Index (RSI)
- TVRD 20.91
- SSSS 48.91
- Support Level
- TVRD $5.65
- SSSS $9.12
- Resistance Level
- TVRD $7.11
- SSSS $10.05
- Average True Range (ATR)
- TVRD 2.47
- SSSS 0.30
- MACD
- TVRD -4.16
- SSSS -0.03
- Stochastic Oscillator
- TVRD 3.26
- SSSS 30.86
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.